CTY ▼ -0.1% - City Therapeutics, Inc.
$CTY - Phase 1 Data for CITY-FXI, an RNAi Therapeutic Candidate for Thromboembolic Diseases, Selected for Oral Presentation at the 68th ASH Annual Meeting
04-NOV-2026 09:01 AM ET
Share this post
More filings for $CTY
CTY ▲ +0.9% - City Therapeutics, Inc.Nov 3, 2026CTY ▼ -4.2% - City Therapeutics, Inc.Oct 19, 2026CTY ▲ +0.0% - City Therapeutics, Inc. Common StockOct 16, 2026
View full $CTY filing history →💬 Comments
Loading comments…
Leave a comment